AbbVie Reports Full-Year and Fourth-Quarter 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Abbvie (ABBV) PT Raised to $212 at Goldman Sachs
February 3, 2025 5:17 AM ESTGoldman Sachs analyst Chris Shibutani raised the price target on Abbvie (NYSE: ABBV) to $212.00 (from $208.00) while maintaining a Buy rating.
The analyst comments "Relative outperformance from ABBV shares (+4.7% on Friday vs. XLV -0.3%) was earned in our view, with continued strong momentum from Skyrizi and Rinvoq enabling the delivery of... More
AbbVie (ABBV) Tops Q4 EPS by 10c, Offers Guidance
January 31, 2025 7:37 AM ESTAbbVie (NYSE: ABBV) reported Q4 EPS of $2.16, $0.10 better than the analyst estimate of $2.06. Revenue for the quarter came in at $15.1 billion versus the consensus estimate of $14.82 billion.
GUIDANCE:
AbbVie sees FY2025 EPS of $12.12-$12.32, versus the consensus of $12.13.
For earnings history and earnings-related data on AbbVie (ABBV) click here.
... More